Search results for: Jorge Mestre-Ferrandiz
Filter search results
Would Waiving COVID-19 Vaccines Patents Save Lives?
18 May 2021
…Efficient Prices for Drugs in a Global Context. Health Economics, 24(3), pp.294–301. https://doi.org/10.1002/hec.3021. Mestre-Ferrandiz, J., Sussex, J. and Towse, A., 2012. The R&D Cost of a New Medicine. [online] Office…
The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
16 November 2022
…Goodall, J., Hirsch, M., Mestre-Ferrandiz, J., Rex J. 2017. Time for a Change in How New Antibiotics are Reimbursed: Development of an Insurance Framework for Funding New Antibiotics based on…
What is the True Value of Spending on Medical Research?
13 February 2012
…Morris, S., Sundmacher, L., Garau, M., Mestre-Ferrandiz, J., Sussex, J., Grant, J., Ismail, S., Nason, E., Wooding, S. and Kapur, S. (2008) Medical research: What’s it worth? Report for the Medical…
Published: OHE Study Projecting UK Medicines Expenditure
30 September 2013
…the greater resources. This may allow policy makers to make better-informed decisions—both about allocating resources and about policies influencing medicines expenditure. O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J….
OHE Study Projecting UK Medicines Expenditure Extended to 2018
18 November 2013
…Methodology and Results 2013-2018 from Office of Health Economics Download: UK NHS Medicines Bill Projection: Methodology and Results 2013-2018 [1]O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J. (2013) Projecting…
Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK
14 March 2017
…Garau, M. and Mestre-Ferrandiz, J. (2009). Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries. OHE Briefing. London: Office of Health Economics. Mestre-Ferrandiz, J., Garau, M., O’Neill,…
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
…Zamora, B., 2018. The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries. OHE Consulting Report, London: Office of Health Economics. RePEc Mestre-Ferrandiz, J., Towse, A.,…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…High Cost Technologies. OHE Briefing. London: Office of Health Economics. | RePEc Karlsberg-Schaffer, S., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and Towse, A., (2018). Paying for Cures: Perspectives on…
Data Governance Arrangements for Real-world Evidence in Japan
12 September 2019
…Challenges. Journal of Comparative Effectiveness Research, 7(12), pp.1133-43. DOI. RePEc. Lee,E.K., Park,J.A., Cole,A. and Mestre-Ferrandiz,J., 2017. Data Governance Arrangements for Real-World Evidence in South Korea. OHE Consulting Report, London: Office…